Alice C. Fan

Publications

• "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. DeChristopher BA, Fan AC, Felsher DW, Wender PA. Oncotarget. 2012; 3 (1): 58-66
• Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Leuk Res. 2012; 36 (1): 98-103
• Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW. Nat Med. 2009; 15 (5): 566-71
• Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Liu Z, Fan AC, Rakhra K, Sherlock S, Goodwin A, Chen X, Yang Q, Felsher DW, Dai H. Angew Chem Int Ed Engl. 2009; 48 (41): 7668-72
• A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Fan AC, Goldrick MM, Ho J, Liang Y, Bachireddy P, Felsher DW. Mol Cancer. 2008: 7 74
• Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW. PLoS One. 2008; 3 (5): e2125
• Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C. To CA, Hsieh RW, McClellan JS, Howard W, Fischbein NJ, Brown JM, Felsher DW, Fan AC. BMJ Case Rep. 2012 2012
• CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW. Cancer Cell. 2010; 18 (5): 485-98
• Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH. Cancer Res. 2010; 70 (23): 9837-45
• Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K, Padiernos E, Boonmark N, Zhu Z, Fan AC, Bailey AS, Fleming WH, Corless C, Felsher DW, Naumovski L, Lopez CD. Proc Natl Acad Sci U S A. 2009; 106 (11): 4390-5
• Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Proc Natl Acad Sci U S A. 2007; 104 (32): 13028-33
• Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW. Blood. 2007; 110 (7): 2674-84
• Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Proc Natl Acad Sci U S A. 2006; 103 (44): 16266-71
• Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW. Semin Cancer Biol. 2004; 14 (1): 3-11
• p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H. Cancer. 2000; 89 (4): 769-73